We are proud to announce that ANTIVIRESPIR is one of the 9 excellence projects selected by an international expert panel as part of the 2024 PEPR MIE Call for Projects, and approved for funding by the General Secretariat for Investment, following a decision by the Prime Minister. The ANTIVIRESPIR project aims to significantly scale up the national infrastructure #Virocrib (@CNRS Biology) by partnering with the #GAVO consortium (Generation of Original Antivirals, @CNRS Chemistry) and the ChemBioFrance research infrastructure. The objective is to synthesize, screen, identify, and characterize innovative antiviral compounds targeting emerging and re-emerging respiratory viruses, with the goal of enabling rapid deployment in the event of a future pandemic.
Within #Virocrib, RESPIVIR and the technological research platform Virnext will contribute to this project by providing its viral library, expertise in combinatorial screening tools, and its continuum of predictive in vitro and in vivo preclinical models of infections caused by respiratory viruses such as influenza, pneumoviruses, coronaviruses, and SARSCoV2.
For more information:
https://anrs.fr/fr/actualites/actualites/laureats-2024-pepr-mie/
www.virocrib.fr
https://respivir.io
www.virnext.fr
EZUS LYON – Université Claude Bernard Lyon 1
RESPIVIR – Université Laval – Centre de recherche du CHU de Québec–Université Laval
CIRI – Inserm – CNRS – ENS de Lyon
Sandrine Belouzard ; Jean Dubuisson ; Jean-Luc Galzi ; Jacques Lebreton ; Florence Mahuteau ; Manuel Rosa-Calatrava ; John De Vos ; Ana Zarubica ; Delphine Muriaux ; Sylvie Guéder